Therapeutics News and Research

RSS

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

MicroConstants acquires access to new nanosizing technology

MicroConstants, a GLP-compliant Contract Research Organization specializing in bioanalytical and pharmacokinetic analysis, has acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier.

9 Mar 2010

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.

9 Mar 2010

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.

9 Mar 2010

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.

9 Mar 2010

GTA's stockholders voted to approve merger between GTA and Pernix Therapeutics

Golf Trust of America, Inc. announced that GTA's stockholders voted to approve the four proposals that were conditions to closing the previously-announced merger between GTA and Pernix Therapeutics, Inc. at a Special Meeting of Stockholders held earlier today.

8 Mar 2010

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

8 Mar 2010

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).

8 Mar 2010

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium.

8 Mar 2010

MS Awareness Week: Time for nation to go orange and move it to end MS

MS Awareness Week March 8-14 is the time for the nation to go orange and move it to end multiple sclerosis, a disease where someone is newly diagnosed every hour of every day. Supported by a Congressional resolution, this year MS Awareness Week and the state of MS research aptly coincide. Move it to create a world free of MS!

8 Mar 2010

Sigma Life Science extends portfolio of knockout rat models with the release of ADME/Tox applications

Sigma® Life Science, an innovative brand of Sigma-Aldrich®, today extended its portfolio of knockout rat models with the announcement of a new suite of models designed to facilitate more predictive absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) studies.

8 Mar 2010

NerPharMa facility receives FDA approval to manufacture CTI's drug pixantrone

Cell Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has completed its inspection of the facility at NerPharMa (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences Srl, in Nerviano, Italy), which manufactures the CTI's drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product.

8 Mar 2010

NAF to hold third annual Ataxia Investigators Meeting in Rosemont

The National Ataxia Foundation, in conjunction with the University of Chicago program in pathobiology and translational neuroscience, will hold its third annual Ataxia Investigators Meeting March 9-11, 2010, at the Hyatt Regency O'Hare, in Rosemont, Ill. A three-day meeting for patients, caregivers and families will follow at the same location.

6 Mar 2010

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2009 and provided an update on its progress.

5 Mar 2010

HMS study suggests new targets for treating Angelman syndrome

Angelman Syndrome is a rare but serious genetic disorder that causes a constellation of developmental problems in affected children, including mental retardation, lack of speech, and in some cases, autism. Over a decade ago, researchers found that AS was caused by mutation in a single gene, but no one had been able to explain how this defect resulted in the debilitating neurological symptoms of the disease.

5 Mar 2010

Proper diagnosis, treatment and good skin care help control acne and rosacea

Acne and rosacea are two seemingly different skin conditions that have one important thing in common: both are chronic and extremely common skin conditions. However, dermatologists recommend that with proper diagnosis, treatment and a healthy dose of good, old-fashioned skin care, acne and rosacea can be less of a nuisance for patients.

5 Mar 2010

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).

5 Mar 2010

Cornerstone Therapeutics' fourth-quarter net revenues increase 48%

Cornerstone Therapeutics Inc. today reported financial results for the three and 12 months ended December 31, 2009.

4 Mar 2010

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. Celldex reported a net loss of $13.5 million, or $0.43 per share, for the fourth quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008.

4 Mar 2010

SXC Health Solutions reports 2009 financial results

SXC Health Solutions Corp., announces its financial results for the three- and twelve-month periods ended December 31, 2009. Financial references are in U.S. dollars unless otherwise indicated.

4 Mar 2010